Neurotransmitter-Inhibiting Peptide

These are short synthetic peptides marketed on a neuromuscular rationale rather than a matrix-building one. Acetyl hexapeptide-8, roughly 890 daltons, copies the amino terminus of SNAP-25 and is proposed to compete for a place in the SNARE complex that docks acetylcholine vesicles at the presynaptic membrane. Pentapeptide-18 derives from enkephalin and acts at presynaptic opioid receptors to damp vesicle release. The claimed endpoint is weaker contraction of the mimetic muscles that fold the overlying skin.

The comparison being invited is with botulinum toxin type A, a roughly 150 kilodalton protein injected into muscle, taken up by nerve terminals and enzymatically cleaving SNAP-25 with catalytic amplification. A topical hexapeptide must instead cross the stratum corneum, traverse epidermis and dermis, and reach a neuromuscular junction at a concentration sufficient for a stoichiometric, non-catalytic interaction. Published support is mostly small, short, often unblinded work with profilometry endpoints.

Regulatory framing settles what these products may say. A cosmetic may only claim to beautify or alter appearance; asserting that an ingredient blocks neurotransmitter release to relax muscle is a claim about physiological function and would make the product an unapproved drug. Hence the pattern where mechanism appears in marketing narrative while the on-pack claim stays at the appearance of lines.

The failure to avoid is treating these as injection substitutes. Taking the reported effects at face value, they are modest, gradual, reversible on stopping and usually measured on crow's feet, whereas an injected neuromodulator produces discrete, dose-dependent paralysis lasting months. Reading a percentage reduction in average roughness from a supplier-funded study as equivalence to a clinical procedure is not a small overstatement.